Prospective Randomized Controlled Clinical Study for Lung Health Beverage in Preventing Radiotherapy-Related Lung Diseases in Locally Advanced Esophageal Cancer

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. pathological confirmed of esophageal squamous cell carcinoma;
•2. TNM stage T3-4N0M0, TxN1-2M0, TxNxM1a (cervical lymph node metastasis);
•3. Patients with expected survival >=6 months;
•4. Patients aged 18 to 80 years;
•5. Patients with ECOG 0-1;
•6. Patients with sufficient main organ function
•(1) Hemopoietic function: hemoglobin >= 100g/L, platelet >= 90 x 10^9/L, neutrophil >= 1.5x10^9/L;
•(2) Renal function: serum creatinine SCR < 1.5 ULN;
•(3) Liver function: ALT and AST < ULN one point five Times, bilirubin <1.5 x ULN;
•7. The patient must sign the informed consent of receiving concurrent radiotherapy and chemotherapy.

•1. Patients who have previously suffered from or complicated with other malignant tumors (except melanoma skin tumors) and whose diseases are not controlled or cured (depending on the disease type of the primary tumor);
•2. Patients who have previously treated with thoracic radiotherapy;
•3. Patients with congenital or acquired immune deficiency;
•4. HIV positive patients, including those who have received antiretroviral therapy; chronic hepatitis B, virus replication period; active period of hepatitis C;
•5. Pregnancy (confirmed by serum or urine beta- hCG test) or lactation period;
•6. The general condition of the patients was poor, KPS < 70;
•7. Patients have conditions that researchers believe may increase the risk of treatment or have serious uncontrollable complications.

发起方

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine